ABCB5 and recessive dystrophic epidermolysis bullosa: Additionally, ABCB5+ MSCs infusions significantly alleviated patient-perceived pruritus, which is consistently rated as the most bothersome symptom in RDEB, and reduced disease severity as measured by clinically meaningful reductions in two relevant disease severity scores, i.e., the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) activity score and the Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa (iscorEB) clinician score [166].